Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vickerman

Showing results (101-110 of 397) with videos related to

Pageof 40
Sort By:
Addiction (Abingdon, England)|January 28, 2020
Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in EnglandZoe Ward, Rosie Reynolds, Linda Campbell, et al.
BMJ (Clinical Research Ed.)|October 6, 2012
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysisGeorgie J MacArthur, Silvia Minozzi, Natasha Martin, et al.
AIDS (London, England)|June 13, 2025
Unit Costs of Opioid Agonist Therapy (OAT): A Global Systematic review and cost ExtrapolationAnh Truc Vo, Adriane Wynn, Marycris Hernandez, et al.
International Journal of Epidemiology|August 16, 2016
HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidenceHannah Fraser, Christinah Mukandavire, Natasha K Martin, et al.
Expert Review of Gastroenterology & Hepatology|January 5, 2018
Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocolDavina Swan, Walter Cullen, Juan Macias, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 28, 2015
What really is a concentrated HIV epidemic and what does it mean for West and Central Africa? Insights from mathematical modelingMarie-Claude Boily, Michael Pickles, Michel Alary, et al.
Plos One|May 26, 2016
The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?Jack Stone, Natasha K Martin, Matthew Hickman, et al.
Addiction (Abingdon, England)|April 15, 2016
Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV preventionNatasha K Martin, Peter Vickerman, Matthew Hickman, et al.
Journal of Viral Hepatitis|January 22, 2019
Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected dataRoss J Harris, Helen E Harris, Sema Mandal, et al.
Eclinicalmedicine|March 7, 2020
Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxisLouis Macgregor, Monica Desai, Natasha K Martin, et al.
Pageof 40

Showing results (101-110 of 397) with videos related to

Sort By:
Pageof 40
Addiction (Abingdon, England)|January 28, 2020
Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in EnglandZoe Ward, Rosie Reynolds, Linda Campbell, et al.
BMJ (Clinical Research Ed.)|October 6, 2012
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysisGeorgie J MacArthur, Silvia Minozzi, Natasha Martin, et al.
AIDS (London, England)|June 13, 2025
Unit Costs of Opioid Agonist Therapy (OAT): A Global Systematic review and cost ExtrapolationAnh Truc Vo, Adriane Wynn, Marycris Hernandez, et al.
International Journal of Epidemiology|August 16, 2016
HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidenceHannah Fraser, Christinah Mukandavire, Natasha K Martin, et al.
Expert Review of Gastroenterology & Hepatology|January 5, 2018
Hepcare Europe - bridging the gap in the treatment of hepatitis C: study protocolDavina Swan, Walter Cullen, Juan Macias, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 28, 2015
What really is a concentrated HIV epidemic and what does it mean for West and Central Africa? Insights from mathematical modelingMarie-Claude Boily, Michael Pickles, Michel Alary, et al.
Plos One|May 26, 2016
The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?Jack Stone, Natasha K Martin, Matthew Hickman, et al.
Addiction (Abingdon, England)|April 15, 2016
Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV preventionNatasha K Martin, Peter Vickerman, Matthew Hickman, et al.
Journal of Viral Hepatitis|January 22, 2019
Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected dataRoss J Harris, Helen E Harris, Sema Mandal, et al.
Eclinicalmedicine|March 7, 2020
Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxisLouis Macgregor, Monica Desai, Natasha K Martin, et al.
Pageof 40